Alessandro Federico, Marianna Murolo, Pasquale Ferranti, Maria Rosaria Rizzo, Paola Stiuso, Michele Caraglia, Carmelina Loguercio, Carmela De Simone, Concetta Tuccillo, Ilaria Scognamiglio, Stiuso, P, Scognamiglio, I, Murolo, M, Ferranti, Pasquale, De Simone, C, Rizzo, Mr, Tuccillo, C, Caraglia, M, Loguercio, C, Federico, A., Stiuso, Paola, Ferranti, P, Rizzo, Maria Rosaria, Caraglia, Michele, Loguercio, Carmelina, and Federico, Alessandro
Liver steatosis can evolve to steatohepatitis (NASH) through a series of biochemical steps related to oxidative stress in hepatocytes. Antioxidants, such as silybin, have been proposed as a treatment of patients with nonalcoholic fatty liver disease (NAFLD) and NASH. In this study, we evaluated, in patients with histologically documented NASH, the oxidant/antioxidant status and lipid “fingerprint” in the serum of NASH patients, both in basal conditions and after 12 months of treatment with silybin-based food integrator Realsil (RA). The oxidant/antioxidant status analysis showed the presence of a group of patients with higher basal severity of disease (NAS scores 4.67 ± 2.5) and a second group corresponding to borderline NASH (NAS scores = 3.8 ± 1.5). The chronic treatment with RA changed the NAS score in both groups that reached the statistical significance only in group 2, in which there was also a significant decrease of serum lipid peroxidation. The lipidomic profile showed a lipid composition similar to that of healthy subjects with a restoration of the values of free cholesterol, lysoPC, SM, and PC only in group 2 of patients after treatment with RA.Conclusion.These data suggest that lipidomic and/or oxidative status of serum from patients with NASH could be useful as prognostic markers of response to an antioxidant treatment.